RedHill Biopharma Ltd. - Form 20-F Summary (Fiscal Year Ended Dec 31, 2013)
Business Context and Reporting Period
Company: RedHill Biopharma Ltd.
Reporting Period: Fiscal year ended December 31, 2013.
Business Model: An emerging Israeli biopharmaceutical company focused on acquiring and developing patent-protected new formulations and combinations of existing drugs. The company targets inflammatory and gastrointestinal (GI) diseases, including cancers.
Stage: Clinical development stage. None of the therapeutic candidates have been approved for marketing or commercialized. The company has incurred losses since inception and expects to continue doing so until regulatory approvals are obtained and commercialization begins.
Key Financial Metrics
| Metric (in thousands USD) | 2013 | 2012 |
|---|---|---|
| Revenues | 12 | 16 |
| Research & Development Expenses | (8,100) | (6,455) |
| General & Administrative Expenses | (2,684) | (2,601) |
| Operating Loss | (10,772) | (9,040) |
| Net Loss (Comprehensive Loss) | (10,628) | (10,326) |
| Cash and Short-Term Investments (Dec 31) | 12,113 | 18,365 |
| Working Capital | 10,186 | 17,485 |
| Total Assets | 14,340 | 20,096 |
| Total Liabilities | 2,415 | 1,078 |
| Accumulated Deficit | (33,260) | (23,887) |
| Loss Per Share (Basic & Diluted) | (0.17) | (0.20) |
Note: The filing does not provide specific cash flow from operating activities in the summary table, but the text indicates net cash used in operating activities was approximately $8.4 million for 2013.
Material Changes vs. Prior Period
- Revenue: Decreased slightly from $16,000 in 2012 to $12,000 in 2013. Revenues remain insignificant and are derived from royalty payments on limited patent rights.
- R&D Expenses: Increased by 25% (from $6.5 million to $8.1 million). The increase was driven by approximately $2.4 million in clinical trial costs for candidates RHB-102, RHB-103, RHB-104, and RHB-105, partially offset by a $1 million discount from a Canadian service provider.
- Operating Loss: Increased by 20% to $10.8 million, primarily due to expanded R&D activities.
- Financial Income/Expense: Shifted from a net financial expense of $1.3 million in 2012 to a net financial income of $0.1 million in 2013. The 2012 expense was largely due to non-cash accretion of royalty obligations, while 2013 income included fair value gains on financial assets and exchange rate benefits.
- Liquidity: Cash and short-term investments decreased from $18.4 million to $12.1 million. However, the company raised approximately $20.2 million in private financings in January 2014 (post-period), bringing cash levels to approximately $34.2 million as of February 23, 2014.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Capital Needs: The company states that its current working capital is insufficient to complete the R&D for all therapeutic candidates. It expects to incur additional losses and will need to raise substantial additional capital through equity or debt financing, or via commercialization agreements. Failure to raise capital could force the company to delay or eliminate programs.
Therapeutic Pipeline Status:
- RHB-101 (Hypertension/Heart Failure): Under review; additional studies required prior to marketing application.
- RHB-102 (Anti-emetic): Discussions with FDA regarding marketing approval pathway; pursuing additional indications.
- RHB-103 (Migraine): NDA filed; received a Complete Response Letter (CRL) from FDA in February 2014 regarding manufacturing and labeling (no safety issues). Response being prepared.
- RHB-104 (Crohn's Disease): Phase III study in North America and Israel ongoing.
- RHB-105 (H. Pylori): Phase III study in the U.S. ongoing.
- RHB-106 (Bowel Prep): In preparation for Phase II/III studies.
Key Risks and Contingencies:
- Regulatory Approval: No products are approved. Clinical trials are lengthy, expensive, and uncertain. Failure to obtain FDA or foreign regulatory approval will prevent commercialization.
- Intellectual Property (RHB-102): The licensor for RHB-102, SCOLR Pharma Inc., ceased operations in 2013. While RedHill has protections under bankruptcy code and has filed its own provisional patent, there is a risk regarding the ability to secure patents and commercialize the product.
- Manufacturing: Reliance on third-party manufacturers. Delays or failures in manufacturing could impact clinical trials and commercialization.
- Geopolitical: Operations are based in Israel; political or military instability in the region could disrupt operations or affect capital raising.
- Dilution: Recent private placements included full ratchet anti-dilution provisions for certain investors, which could result in substantial dilution if future securities are issued below specific price thresholds.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $34.2 million cash balance (as of Feb 2014) against the projected costs of ongoing Phase III trials for RHB-104 and RHB-105, and the timeline for potential additional financing.
- RHB-103 FDA Response: Monitor the status of the response to the FDA's Complete Response Letter received in February 2014 and the expected timeline for approval.
- RHB-102 IP Status: Confirm the legal standing of the RHB-102 patent rights following the cessation of operations by the original licensor, SCOLR Pharma.
- Anti-Dilution Provisions: Review the terms of the January 2014 private placements (OrbiMed/Broadfin and Israeli investors) to understand the potential for future dilution if share prices fall below $9.50 (ADS) or NIS 3.9 (Ordinary Shares).
- Clinical Trial Progress: Track patient enrollment and interim results for the Phase III trials of RHB-104 (Crohn's) and RHB-105 (H. Pylori).